UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
                                      1934

         Date of Report (Date of earliest event reported) August 9, 2006

                         Calypte Biomedical Corporation
               (Exact name of Company as specified in its charter)

           Delaware                     000-20985                06-1226727
(State or Other Jurisdiction)   (Commission File Number)      (I.R.S. Employer
      of Incorporation)                                        Identification)

             5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035

               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282

                                       N/A

          (Former name or former address, if changed since last report)

|_|   Written communication pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 40.13e-4(c))

<PAGE>

Item 7.01 - Regulation FD Disclosure.

On August 9, 2006, Calypte Biomedical Corporation (the "Company") held a webcast
conference call with analysts and investors, during which Roger I. Gale, the
Company's Chairman and Chief Executive Officer, and Theodore R. Gwin, the
Company's Chief Financial Officer, discussed the Company's financial results for
the quarter ended June 30, 2006 and provided an update on the Company's
operations. A copy of the prepared remarks of Messrs. Gale and Gwin is attached
as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01 - Financial Statements and Exhibits.

(d) Exhibits

Exhibit
 Number   Description
-------   ----------------------------------------------------------------------
  99.1    Prepared Remarks of Roger I. Gale and Theodore R. Gwin for Calypte
          Biomedical Corporation Second Quarter 2006 Analyst/Investor Conference
          Call held on August 9, 2006.

                                   SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date: August 15, 2006

                                        Calypte Biomedical Corporation


                                        By: /s/ Theodore R. Gwin
                                            ------------------------------------
                                            Theodore R. Gwin
                                            Chief Financial Officer
{"company-data": {"conformed-name": "CALYPTE BIOMEDICAL CORP", "cik": "0000899426", "assigned-sic": "3826", "irs-number": "061226727", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-32280", "film-number": "061036471"}, "business-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588", "phone": "9257307200"}, "mail-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
                                      1934

         Date of Report (Date of earliest event reported) August 9, 2006

                         Calypte Biomedical Corporation
               (Exact name of Company as specified in its charter)

           Delaware                     000-20985                06-1226727
(State or Other Jurisdiction)   (Commission File Number)      (I.R.S. Employer
      of Incorporation)                                        Identification)

             5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035

               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282

                                       N/A

          (Former name or former address, if changed since last report)

|_|   Written communication pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 40.13e-4(c))
Item 7.01 - Regulation FD Disclosure.

On August 9, 2006, Calypte Biomedical Corporation (the "Company") held a webcast
conference call with analysts and investors, during which Roger I. Gale, the
Company's Chairman and Chief Executive Officer, and Theodore R. Gwin, the
Company's Chief Financial Officer, discussed the Company's financial results for
the quarter ended June 30, 2006 and provided an update on the Company's
operations. A copy of the prepared remarks of Messrs. Gale and Gwin is attached
as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01 - Financial Statements and Exhibits.

(d) Exhibits

Exhibit
 Number   Description
-------   ----------------------------------------------------------------------
  99.1    Prepared Remarks of Roger I. Gale and Theodore R. Gwin for Calypte
          Biomedical Corporation Second Quarter 2006 Analyst/Investor Conference
          Call held on August 9, 2006.

                                   SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date: August 15, 2006

                                        Calypte Biomedical Corporation

                                        By: /s/ Theodore R. Gwin
                                            ------------------------------------
                                            Theodore R. Gwin
                                            Chief Financial Officer